Prognosis of Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization(MC-hccAI 001): Development and Validation of the ALFP Score
Baocuo Gong,1,2,* Xuewen Wang,1,3,* Wanting Guo,1 Hongyi Yang,1 Yanhong Shi,1 Yaying Chen,1 Simiao Gao,1 Jialin Chen,1 Lifang Liu,2 Linbin Lu,1 Xiong Chen1 On behalf of Fujian HCC-biomarker Study Group1Department of Oncology, Mengchao Hepatobiliary Hospital of Fujian Medical Universi...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-08-01
|
| Series: | Journal of Hepatocellular Carcinoma |
| Subjects: | |
| Online Access: | https://www.dovepress.com/prognosis-of-patients-with-hepatocellular-carcinoma-treated-with-trans-peer-reviewed-fulltext-article-JHC |
| _version_ | 1797743873085145088 |
|---|---|
| author | Gong B Wang X Guo W Yang H Shi Y Chen Y Gao S Chen J Liu L Lu L Chen X |
| author_facet | Gong B Wang X Guo W Yang H Shi Y Chen Y Gao S Chen J Liu L Lu L Chen X |
| author_sort | Gong B |
| collection | DOAJ |
| description | Baocuo Gong,1,2,* Xuewen Wang,1,3,* Wanting Guo,1 Hongyi Yang,1 Yanhong Shi,1 Yaying Chen,1 Simiao Gao,1 Jialin Chen,1 Lifang Liu,2 Linbin Lu,1 Xiong Chen1 On behalf of Fujian HCC-biomarker Study Group1Department of Oncology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, 350025, People’s Republic of China; 2Department of Oncology, Oriental Hospital Affiliated to Xiamen University, Fuzhou, Fujian, 350025, People’s Republic of China; 3Department of Histology and Embryology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, 350122, People’s Republic of China*These authors contributed equally to this workCorrespondence: Linbin Lu; Xiong Chen, Department of Oncology, Mengchao Hepatobiliary Hospital of Fujian Medical University, 321 Xihong Road, Fuzhou, Fujian, 350025, People’s Republic of China, Email doctorxiaolin@fjmu.edu.cn; cxiongzpc@fjmu.edu.cnBackground: Transarterial chemoembolization (TACE) is the recommended first-line treatment for intermediate-stage Hepatocellular carcinoma (HCC) patients. However, predicting the survival of HCC patients receiving TACE remains challenging.Methods: In this retrospective study, we analyzed a total of 1805 HCC patients who received TACE. The patients were randomly divided into a training set (n = 1264) and a validation set (n = 541). We examined various prognostic factors within the training set and developed a simple ALFP (ALBI grade, AFP, and Prothrombin time) score, which was subsequently validated using the independent validation set.Results: Our multivariate analysis revealed that baseline ALBI grade 2 or 3, AFP ≥ 100 ng/mL, and PT > 13.1 s were independent unfavorable prognostic factors for HCC patients receiving TACE (p 13.1 s. The score has a range of 0 to 3, and higher scores are associated with poorer outcomes. The median overall survival (OS) varied significantly among different ALFP score groups, both in the training set and the validation set (p |
| first_indexed | 2024-03-12T15:01:44Z |
| format | Article |
| id | doaj.art-ac5dd02370564f5092d45942ec68175e |
| institution | Directory Open Access Journal |
| issn | 2253-5969 |
| language | English |
| last_indexed | 2024-03-12T15:01:44Z |
| publishDate | 2023-08-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Hepatocellular Carcinoma |
| spelling | doaj.art-ac5dd02370564f5092d45942ec68175e2023-08-13T22:16:47ZengDove Medical PressJournal of Hepatocellular Carcinoma2253-59692023-08-01Volume 101341135185849Prognosis of Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization(MC-hccAI 001): Development and Validation of the ALFP ScoreGong BWang XGuo WYang HShi YChen YGao SChen JLiu LLu LChen XBaocuo Gong,1,2,* Xuewen Wang,1,3,* Wanting Guo,1 Hongyi Yang,1 Yanhong Shi,1 Yaying Chen,1 Simiao Gao,1 Jialin Chen,1 Lifang Liu,2 Linbin Lu,1 Xiong Chen1 On behalf of Fujian HCC-biomarker Study Group1Department of Oncology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, 350025, People’s Republic of China; 2Department of Oncology, Oriental Hospital Affiliated to Xiamen University, Fuzhou, Fujian, 350025, People’s Republic of China; 3Department of Histology and Embryology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, 350122, People’s Republic of China*These authors contributed equally to this workCorrespondence: Linbin Lu; Xiong Chen, Department of Oncology, Mengchao Hepatobiliary Hospital of Fujian Medical University, 321 Xihong Road, Fuzhou, Fujian, 350025, People’s Republic of China, Email doctorxiaolin@fjmu.edu.cn; cxiongzpc@fjmu.edu.cnBackground: Transarterial chemoembolization (TACE) is the recommended first-line treatment for intermediate-stage Hepatocellular carcinoma (HCC) patients. However, predicting the survival of HCC patients receiving TACE remains challenging.Methods: In this retrospective study, we analyzed a total of 1805 HCC patients who received TACE. The patients were randomly divided into a training set (n = 1264) and a validation set (n = 541). We examined various prognostic factors within the training set and developed a simple ALFP (ALBI grade, AFP, and Prothrombin time) score, which was subsequently validated using the independent validation set.Results: Our multivariate analysis revealed that baseline ALBI grade 2 or 3, AFP ≥ 100 ng/mL, and PT > 13.1 s were independent unfavorable prognostic factors for HCC patients receiving TACE (p 13.1 s. The score has a range of 0 to 3, and higher scores are associated with poorer outcomes. The median overall survival (OS) varied significantly among different ALFP score groups, both in the training set and the validation set (phttps://www.dovepress.com/prognosis-of-patients-with-hepatocellular-carcinoma-treated-with-trans-peer-reviewed-fulltext-article-JHCalbumin-bilirubin grade；α-fetoprotein； prothrombin time； transarterial chemoembolization； hepatocellular carcinoma. |
| spellingShingle | Gong B Wang X Guo W Yang H Shi Y Chen Y Gao S Chen J Liu L Lu L Chen X Prognosis of Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization(MC-hccAI 001): Development and Validation of the ALFP Score Journal of Hepatocellular Carcinoma albumin-bilirubin grade；α-fetoprotein； prothrombin time； transarterial chemoembolization； hepatocellular carcinoma. |
| title | Prognosis of Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization(MC-hccAI 001): Development and Validation of the ALFP Score |
| title_full | Prognosis of Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization(MC-hccAI 001): Development and Validation of the ALFP Score |
| title_fullStr | Prognosis of Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization(MC-hccAI 001): Development and Validation of the ALFP Score |
| title_full_unstemmed | Prognosis of Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization(MC-hccAI 001): Development and Validation of the ALFP Score |
| title_short | Prognosis of Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization(MC-hccAI 001): Development and Validation of the ALFP Score |
| title_sort | prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization mc hccai 001 development and validation of the alfp score |
| topic | albumin-bilirubin grade；α-fetoprotein； prothrombin time； transarterial chemoembolization； hepatocellular carcinoma. |
| url | https://www.dovepress.com/prognosis-of-patients-with-hepatocellular-carcinoma-treated-with-trans-peer-reviewed-fulltext-article-JHC |
| work_keys_str_mv | AT gongb prognosisofpatientswithhepatocellularcarcinomatreatedwithtransarterialchemoembolizationmchccai001developmentandvalidationofthealfpscore AT wangx prognosisofpatientswithhepatocellularcarcinomatreatedwithtransarterialchemoembolizationmchccai001developmentandvalidationofthealfpscore AT guow prognosisofpatientswithhepatocellularcarcinomatreatedwithtransarterialchemoembolizationmchccai001developmentandvalidationofthealfpscore AT yangh prognosisofpatientswithhepatocellularcarcinomatreatedwithtransarterialchemoembolizationmchccai001developmentandvalidationofthealfpscore AT shiy prognosisofpatientswithhepatocellularcarcinomatreatedwithtransarterialchemoembolizationmchccai001developmentandvalidationofthealfpscore AT cheny prognosisofpatientswithhepatocellularcarcinomatreatedwithtransarterialchemoembolizationmchccai001developmentandvalidationofthealfpscore AT gaos prognosisofpatientswithhepatocellularcarcinomatreatedwithtransarterialchemoembolizationmchccai001developmentandvalidationofthealfpscore AT chenj prognosisofpatientswithhepatocellularcarcinomatreatedwithtransarterialchemoembolizationmchccai001developmentandvalidationofthealfpscore AT liul prognosisofpatientswithhepatocellularcarcinomatreatedwithtransarterialchemoembolizationmchccai001developmentandvalidationofthealfpscore AT lul prognosisofpatientswithhepatocellularcarcinomatreatedwithtransarterialchemoembolizationmchccai001developmentandvalidationofthealfpscore AT chenx prognosisofpatientswithhepatocellularcarcinomatreatedwithtransarterialchemoembolizationmchccai001developmentandvalidationofthealfpscore |